logo
Book a meeting
AEON Biopharma

Aeon Biopharma

Pharmaceuticals, 5 Park PLZ, Irvine, California, 92614, United States, 1-10 Employees

aeonbiopharma.com

  • LinkedIn

phone no Phone Number: 94********

Who is AEON BIOPHARMA

AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated t...

Read More

lock icon Get Full Access
map
  • 5 Park PLZ, Irvine, California, 92614, United States Headquarters: 5 Park PLZ, Irvine, California, 92614, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • Kathleen Johnson CEO:   Kathleen Johnson

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from AEON BIOPHARMA

AEON Biopharma Org Chart and Mapping

Kathleen Johnson

Kathleen Johnson

Executive Assistant to Chief Executive Officer

Employees
Alex Wilson

Alex Wilson

EVP, Chief Legal Officer & Corporate Secretary

See Full Org Chart arrow
email-formate-icon
View Email Formats for AEON Biopharma
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding AEON Biopharma

Answer: AEON Biopharma's headquarters are located at 5 Park PLZ, Irvine, California, 92614, United States

Answer: AEON Biopharma's phone number is 94********

Answer: AEON Biopharma's official website is https://aeonbiopharma.com

Answer: AEON Biopharma's revenue is $5 Million to $10 Million

Answer: AEON Biopharma's SIC: 2834

Answer: AEON Biopharma has 1-10 employees

Answer: AEON Biopharma is in Pharmaceuticals

Answer: AEON Biopharma contact info: Phone number: 94******** Website: https://aeonbiopharma.com

Answer: AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access